Table 2.
Results of MRproANP and sST2 Assessments
| Total, N=105 | No Recurrence, n=71 | Recurrence, n=34 | P Value* | |
|---|---|---|---|---|
| MRproANP PV, pmol/L | 131.3 (73.5–200.6) | 97.1 (60.9–150.7) | 192.2 (155.9–263.9) | <0.01 |
| MRproANP LA, pmol/L | 143.5 (89.8–208.3) | 110.7 (79.3–172.1) | 234.3 (163.4–334.2) | <0.01 |
| MRproANP RA, pmol/L | 142.2 (90.3–210.3) | 108.8 (81.8–168.1) | 207.8 (159.1–347.2) | <0.01 |
| sST2 PV, ng/mL | 26.4 (19.5–36.4) | 23.4 (17.4–33.0) | 30.3 (23.3–39.8) | <0.01 |
Values are provided as median (quartile 1–quartile 3). MRproANP indicates midregional N‐terminal pro–atrial natriuretic peptide; MRproANP LA, level of midregional N‐terminal pro–atrial natriuretic peptide measured in blood drawn from the left atrium; MRproANP PV, midregional N‐terminal pro–atrial natriuretic peptide measured in peripheral venous blood; MRproANP RA, level of midregional N‐terminal pro–atrial natriuretic peptide measured in blood drawn from the right atrium; sST2, level of soluble suppression of tumorigenicity 2; and sST2 PV, soluble suppression of tumorigenicity 2 measured in peripheral venous blood.
*
P values from Mann–Whitney tests.